<DOC>
	<DOC>NCT02059720</DOC>
	<brief_summary>A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.</brief_summary>
	<brief_title>Haplo-SCT vs ASCT With or Without Decitabine in AML CR1</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Age &gt;= 18y Diagnosed as AML (except acute promyelocytic leukemia M3) for the first time Minimal Residual Disease (MRD) test can be achieved (molecular biology first if applicatable, and/or cytogenetics and/or immunophenotyping) Presence of an available haplomismatch related donor Contraindications of chemotherapy or hematopoietic stem cell transplantation Presence of an available identical sibling donor or a 10/10 HLA locimatched unrelated donor Participating in other clinical trials concerning the prophylaxis of disease recurrence after ASCT No effective contraception Pregnant or lactating females Other causes which are not suitable for the trial in investigator's consideration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>autologous hematopoietic stem cell transplantation</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>